Month: February 2024

Company continues to make strides towards breakeven NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year. Both pathology and products divisions have demonstrated substantial growth from 2023, with the pathology services division increasing revenue by 52%, and the products division increasing revenue by 115%. The growth of revenues in both of these divisions, alongside the cost-cutting measures executed by the company during 2023, has driven the substantial reduction in cash burn from operations, as was recently reported. With a $1.5M cash balance ending 2023, the company is positioned to achieve its goal of reaching profitability. “Continued...

Repeat Orders from the Israel Defense Forces and Israeli police forces since October 2023 accumulates to over $4.85 million Netanya, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, today announced that it has received repeat purchase orders of approximately $550,000 since the beginning of 2024 from the Israel Defense Forces and Israeli police forces, for its advanced military headset system family of products.   Since October 2023, the Company has received over $4.85 million in orders from the Israel Defense Forces and Israeli police forces. “Repeat orders serve as a strong indicator and confirmation of the distinct capabilities and effective deployment of our innovative in-ear headset...

E-Cite Motors Goes ICE ICE Baby! BOTHELL, WA, Feb. 13, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – VaporBrands International, Inc. dba E-Cite Motors Group, (OTC:VAPR) reveals that it will offer gas powered versions of its “GT” and “C3” mid-engine sports car models previously only to be available as all electric.  Both models will be available with gasoline internal combustion engines (ICE) and current electric (EV) options. The petrol-powered version of the GT will bear the designation of “IC-GT” and the electric version the “EV-GT”, whereas the C3 model “IC-C3” and “EV-C3” respectively. E-Cite’s GT model has been formally approved by the National Highway Traffic Safety Administration “NHTSA” in accordance with (49 CFR Part 586) to be “new vehicles” legally driven on public roads in the US and the C3’s submission is currently under...

AI-Media Launches LEXI RecordedLEXI Recorded offers fast turnaround, is cost competitive, has excellent accuracy and integration options for captioning recorded content.BROOKLYN, N.Y., Feb. 13, 2024 (GLOBE NEWSWIRE) — AI-Media is excited to announce the launch of its VOD automated captioning solution, LEXI Recorded. This groundbreaking product, created initially for a major sporting franchise, utilizes the cutting-edge AI (Artificial Intelligence) technology of their flagship LEXI product. LEXI Recorded will address the ever-increasing demand for high volume, fast turnaround and easy captioning of recorded content, while ensuring high accuracy and cost-effectiveness. It is also capable of seamlessly integrating with a customer’s media management system, to become an end-to-end media production workflow, and delivering...

Expands patent estate covering Adial’s unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence CHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it has been awarded an important patent which expands the estate covering the combination of the Company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and drug dependencies, such as opioid use disorder (OUD), with the Company’s lead investigational new drug product AD04. “Following a post hoc analysis of our...